全文获取类型
收费全文 | 235532篇 |
免费 | 6053篇 |
国内免费 | 147篇 |
专业分类
耳鼻咽喉 | 1602篇 |
儿科学 | 8914篇 |
妇产科学 | 4756篇 |
基础医学 | 25244篇 |
口腔科学 | 2812篇 |
临床医学 | 20507篇 |
内科学 | 42433篇 |
皮肤病学 | 1839篇 |
神经病学 | 22633篇 |
特种医学 | 10441篇 |
外科学 | 34168篇 |
综合类 | 2861篇 |
现状与发展 | 1篇 |
一般理论 | 82篇 |
预防医学 | 25047篇 |
眼科学 | 3635篇 |
药学 | 13275篇 |
2篇 | |
中国医学 | 732篇 |
肿瘤学 | 20748篇 |
出版年
2023年 | 617篇 |
2022年 | 413篇 |
2021年 | 1710篇 |
2020年 | 1373篇 |
2019年 | 2107篇 |
2018年 | 23780篇 |
2017年 | 18836篇 |
2016年 | 21090篇 |
2015年 | 2836篇 |
2014年 | 3296篇 |
2013年 | 4293篇 |
2012年 | 12025篇 |
2011年 | 25940篇 |
2010年 | 21365篇 |
2009年 | 13936篇 |
2008年 | 23434篇 |
2007年 | 25712篇 |
2006年 | 4515篇 |
2005年 | 6019篇 |
2004年 | 6979篇 |
2003年 | 7582篇 |
2002年 | 5449篇 |
2001年 | 711篇 |
2000年 | 673篇 |
1999年 | 516篇 |
1998年 | 711篇 |
1997年 | 593篇 |
1996年 | 415篇 |
1995年 | 490篇 |
1994年 | 414篇 |
1993年 | 364篇 |
1992年 | 254篇 |
1991年 | 268篇 |
1990年 | 292篇 |
1989年 | 203篇 |
1988年 | 199篇 |
1987年 | 155篇 |
1986年 | 143篇 |
1985年 | 145篇 |
1984年 | 133篇 |
1983年 | 128篇 |
1982年 | 175篇 |
1981年 | 141篇 |
1980年 | 148篇 |
1979年 | 74篇 |
1978年 | 82篇 |
1977年 | 60篇 |
1976年 | 59篇 |
1938年 | 61篇 |
1932年 | 58篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
1.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
2.
3.
4.
5.
Amy Body Hans Prenen Marissa Lam Amy Davies Samuel Tipping-Smith Caroline Lum Elizabeth Liow Eva Segelov 《Clinical colorectal cancer》2021,20(1):29-41
Locally advanced rectal cancer has a rising global incidence. Over the last 4 decades, advances first in surgery and later in radiotherapy and chemoradiotherapy have improved outcomes, particularly with regard to local recurrence. Unfortunately, distant metastases remain a significant problem. In clinical trials of patients with stage II and III disease, distant relapse occurs in 25% to 30% of patients regardless of the treatment approach. Recent phase 3 trials have therefore focused on intensification of systemic therapy for localized disease, with an aim of reducing the distant relapse rate. Early results of trials of total neoadjuvant therapy with combination systemic therapy provided in the neoadjuvant setting are promising; for the first time, a significant improvement in the rate of distant relapse has been noted. Longer-term follow-up is eagerly awaited. On the other hand, trimodal therapy with chemotherapy, radiotherapy, and surgery is toxic. Several trials are currently assessing the feasibility of a watch-and-wait approach, omitting surgery in those with complete response to neoadjuvant treatment, in an attempt to reduce the burden of treatment on patients. The future for rectal cancer patients is likely to be highly personalized, with more intense approaches for high-risk patients and omission of unnecessary therapy for those whose disease responds well to initial treatment. Biomarkers such as circulating tumor DNA will help to more accurately stratify patients into risk groups. Improvements in survival and quality of life are expected as the results of ongoing research become available throughout the next decade. 相似文献
6.
George Haddad Malte Klling Urs A. Wegmann Angela Dettling Harald Seeger Roland Schmitt Inga Soerensen-Zender Hermann Haller Andreas D. Kistler Anne Dueck Stefan Engelhardt Thomas Thum Thomas F. Mueller Rudolf P. Wüthrich Johan M. Lorenzen 《Journal of the American Society of Nephrology : JASN》2021,32(2):323
7.
Viviane Rostirola Elsner Lucieli Trevizol Isadora de Leon Marcos da Silva Thayn Weiss Milena Braga Daniela Pochmann Amanda Stolzenberg Blembeel Caroline Dani Elenice Boggio 《中国神经再生研究》2021,16(5):805
A growing body of evidence has suggested that the imbalance of epigenetic markers and oxidative stress appears to be involved in the pathophysiology and progression of stroke. Thus, strategies that modulate these biomarkers might be considered targets for neuroprotection and novel therapeutic opportunities for these patients. Physical exercise has been reported to induce changes in these epigenetic markers and improve clinical outcomes in different populations. However, little is reported on this in post-stroke patients. The purpose of this study was to investigate the effect of a single exercise session with Walk Aide functional electrical stimulation(FES) on cognitive performance, clinical functional parameters, oxidative stress and epigenetic modulation in post-stroke individuals. In this crossover design study, 12 post-stroke individuals aged 54–72 years of either sexes were included and subjected to a single session of exercise(45 minutes) without Walk Aide functional electrical stimulation(EXE alone group), followed by another single session of exercise(45 minutes) with Walk Aide functional electrical stimulation(EXE + FES group). The clinical functional outcome measures, cognitive performance and blood collections for biomarker measurements were assessed pre-and post-intervention. After intervention, higher Berg Balance Scale scores were obtained in the EXE + FES group than in the EXE alone group. There was no significant difference in the Timed Up and Go test results post-intervention between EXE alone and EXE + FES groups. After intervention, a better cognitive performance was found in both groups compared with before the intervention. After intervention, the Timed Up and Go test scores were higher in the EXE + FES group than in the EXE alone group. In addition, the intervention induced lower levels of lipid peroxidation. After intervention, carbonyl level was lower, superoxide dismutase activity and superoxide dismutase/catalase activity ratio were higher in the EXE + FES group, compared with the EXE group alone. In each group, both histone deacetylase(HDAC2) and histone acetyltransferase activities were increased after intervention compared with before the intervention. These findings suggest that a single exercise session with Walk Aide FES is more effective on balance ability and cognitive performance compared with conventional exercise alone in post-stroke patients. This is likely to be related to the regulation of oxidative stress markers. The present study was approved by the Research Ethics Committee of the Methodist University Center-IPA(approval No. 2.423.376) on December 7, 2017 and registered in the Brazilian Registry of Clinical Trials—Re BEC(RBR-9 phj2 q) on February 11, 2019. 相似文献
8.
9.
10.
Kever Anne Buyukturkoglu Korhan Riley Claire S. De Jager Philip L. Leavitt Victoria M. 《Journal of neurology》2021,268(5):1827-1836
Journal of Neurology - To investigate associations of social support to psychological well-being, cognition, and motor functioning in patients with multiple sclerosis (MS). Secondarily, we were... 相似文献